6,686 Shares in Biogen Inc. $BIIB Acquired by Paragon Capital Management Inc.

Key Points

• Paragon Capital Management bought a new position of 6,686 Biogen shares in Q4, valued at approximately $1.177 million.
• Q4 results beat—Biogen reported $1.99 EPS vs. $1.61 expected on $2.28B revenue (down 7.2% YoY) and set FY2026 guidance of 15.25–16.25 EPS (analysts expect ~15.83).
• Institutional investors own 87.93% of BIIB, an insider recently sold 2,660 shares, and analysts show a mixed view with a consensus "Hold" and a $207.92 target; the stock trades at a ~19.6 P/E with a $25.39B market cap.

Paragon Capital Management Inc. bought a new position in Biogen Inc. (NASDAQ:BIIB - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The firm bought 6,686 shares of the biotechnology company's stock, valued at approximately $1,177,000.

Other institutional investors also recently bought and sold shares of the company. GoalVest Advisory LLC acquired a new stake in Biogen in the 4th quarter worth approximately $35,000. Accredited Wealth Management LLC boosted its stake in Biogen by 1,233.3% in the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 185 shares in the last quarter. Elevation Wealth Partners LLC lifted its stake in Biogen by 412.8% during the 4th quarter. Elevation Wealth Partners LLC now owns 200 shares of the biotechnology company's stock valued at $35,000 after acquiring an additional 161 shares during the period. True Wealth Design LLC lifted its stake in Biogen by 62.9% during the 3rd quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company's stock valued at $33,000 after acquiring an additional 90 shares during the period. Finally, WFA of San Diego LLC acquired a new stake in Biogen during the 2nd quarter valued at approximately $32,000. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Biogen Stock Performance

BIIB opened at $172.97 on Monday. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.68 and a quick ratio of 2.03. The firm has a fifty day moving average price of $186.59 and a 200 day moving average price of $172.95. Biogen Inc. has a 1 year low of $112.18 and a 1 year high of $202.41. The stock has a market cap of $25.39 billion, a P/E ratio of 19.63, a P/E/G ratio of 2.31 and a beta of 0.16.

Biogen (NASDAQ:BIIB - Get Free Report) last posted its earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.61 by $0.38. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The firm had revenue of $2.28 billion during the quarter, compared to analysts' expectations of $2.21 billion. During the same period in the previous year, the business posted $3.44 EPS. The business's revenue was down 7.2% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Equities research analysts anticipate that Biogen Inc. will post 15.83 earnings per share for the current year.

Insider Activity

In related news, insider Priya Singhal sold 2,660 shares of the business's stock in a transaction on Monday, February 9th. The shares were sold at an average price of $199.83, for a total value of $531,547.80. Following the completion of the transaction, the insider directly owned 8,043 shares in the company, valued at $1,607,232.69. The trade was a 24.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.18% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts have commented on BIIB shares. The Goldman Sachs Group restated a "buy" rating on shares of Biogen in a research note on Monday, February 9th. UBS Group started coverage on shares of Biogen in a research note on Tuesday, January 6th. They set a "neutral" rating and a $185.00 price objective for the company. Wells Fargo & Company lifted their price objective on shares of Biogen from $190.00 to $200.00 and gave the company an "equal weight" rating in a research note on Sunday, February 8th. Citigroup lifted their price objective on shares of Biogen from $185.00 to $215.00 and gave the company a "neutral" rating in a research note on Monday, February 9th. Finally, Oppenheimer lifted their price objective on shares of Biogen from $250.00 to $275.00 and gave the company an "outperform" rating in a research note on Wednesday, April 1st. Twelve investment analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Biogen has an average rating of "Hold" and a consensus target price of $207.92.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.

Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.